Perioperative ketorolac in high risk breast cancer patients

Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial

Patrice Forget* (Corresponding Author), Martine Berlière, Aline van Maanen, Francois P. Duhoux, Jean-Pascal Machiels, Pierre G. Coulie, Gauthier Bouche, Marc De Kock, Ketorolac in Breast Cancer trial (KBCtrial) group

*Corresponding author for this work

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called “Ketorolac in Breast Cancer trial” (KBCt) (NCT01806259).
Original languageEnglish
Pages (from-to)707-712
Number of pages6
JournalMedical Hypotheses
Volume81
Issue number4
Early online date9 Aug 2013
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Ketorolac
Randomized Controlled Trials
Placebos
Breast Neoplasms
Non-Steroidal Anti-Inflammatory Agents
Neutrophils
Lymphocytes

Cite this

Forget, P., Berlière, M., van Maanen, A., Duhoux, F. P., Machiels, J-P., Coulie, P. G., ... Ketorolac in Breast Cancer trial (KBCtrial) group (2013). Perioperative ketorolac in high risk breast cancer patients: Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial. Medical Hypotheses, 81(4), 707-712. https://doi.org/10.1016/j.mehy.2013.07.033

Perioperative ketorolac in high risk breast cancer patients : Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial. / Forget, Patrice (Corresponding Author); Berlière, Martine; van Maanen, Aline; Duhoux, Francois P.; Machiels, Jean-Pascal; Coulie, Pierre G.; Bouche, Gauthier; De Kock, Marc; Ketorolac in Breast Cancer trial (KBCtrial) group.

In: Medical Hypotheses, Vol. 81, No. 4, 10.2013, p. 707-712.

Research output: Contribution to journalArticle

Forget, P, Berlière, M, van Maanen, A, Duhoux, FP, Machiels, J-P, Coulie, PG, Bouche, G, De Kock, M & Ketorolac in Breast Cancer trial (KBCtrial) group 2013, 'Perioperative ketorolac in high risk breast cancer patients: Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial', Medical Hypotheses, vol. 81, no. 4, pp. 707-712. https://doi.org/10.1016/j.mehy.2013.07.033
Forget, Patrice ; Berlière, Martine ; van Maanen, Aline ; Duhoux, Francois P. ; Machiels, Jean-Pascal ; Coulie, Pierre G. ; Bouche, Gauthier ; De Kock, Marc ; Ketorolac in Breast Cancer trial (KBCtrial) group. / Perioperative ketorolac in high risk breast cancer patients : Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial. In: Medical Hypotheses. 2013 ; Vol. 81, No. 4. pp. 707-712.
@article{2ed18b53362540d2ad19ab335dc1b270,
title = "Perioperative ketorolac in high risk breast cancer patients: Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial",
abstract = "Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called “Ketorolac in Breast Cancer trial” (KBCt) (NCT01806259).",
author = "Patrice Forget and Martine Berli{\`e}re and {van Maanen}, Aline and Duhoux, {Francois P.} and Jean-Pascal Machiels and Coulie, {Pierre G.} and Gauthier Bouche and {De Kock}, Marc and {Ketorolac in Breast Cancer trial (KBCtrial) group}",
note = "Financial support This work is financed by Reliable Cancer Therapies and supported by the Belgian Society of Anaesthesia and Resuscitation, the Fondation Saint-Luc, the Departments of Anesthesiology, and the Commission du Patrimoine of the Universit{\'e} catholique de Louvain, St-Luc Hospital.",
year = "2013",
month = "10",
doi = "10.1016/j.mehy.2013.07.033",
language = "English",
volume = "81",
pages = "707--712",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Perioperative ketorolac in high risk breast cancer patients

T2 - Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial

AU - Forget, Patrice

AU - Berlière, Martine

AU - van Maanen, Aline

AU - Duhoux, Francois P.

AU - Machiels, Jean-Pascal

AU - Coulie, Pierre G.

AU - Bouche, Gauthier

AU - De Kock, Marc

AU - Ketorolac in Breast Cancer trial (KBCtrial) group

N1 - Financial support This work is financed by Reliable Cancer Therapies and supported by the Belgian Society of Anaesthesia and Resuscitation, the Fondation Saint-Luc, the Departments of Anesthesiology, and the Commission du Patrimoine of the Université catholique de Louvain, St-Luc Hospital.

PY - 2013/10

Y1 - 2013/10

N2 - Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called “Ketorolac in Breast Cancer trial” (KBCt) (NCT01806259).

AB - Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called “Ketorolac in Breast Cancer trial” (KBCt) (NCT01806259).

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84883765692&partnerID=MN8TOARS

U2 - 10.1016/j.mehy.2013.07.033

DO - 10.1016/j.mehy.2013.07.033

M3 - Article

VL - 81

SP - 707

EP - 712

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 4

ER -